translat
basic
biomed
research
discoveri
robust
pipelin
product
yield
licens
appropri
usabl
afford
equit
access
tool
diagnost
vaccin
drug
devic
essenti
achiev
univers
global
health
defin
director
nation
center
advanc
translat
scienc
ncat
term
translat
biomedicin
refer
process
turn
observ
laboratori
clinic
commun
intervent
improv
health
individu
public
multistep
bidirect
process
determin
reproduc
robust
laboratori
discoveri
translat
research
appropri
feasibl
advanc
critic
path
product
clinic
develop
toward
licensur
commerci
public
health
intervent
figur
tradit
respons
role
primarili
led
privat
pharmaceut
corpor
biotech
recent
due
competit
highriskhighreward
market
privat
biopharmaceut
corpor
reli
univers
place
captur
next
gener
entrepreneur
incub
space
facilit
incept
innov
idea
lead
discoveri
merit
develop
addit
organ
wipo
search
administ
world
intellectu
properti
organ
wipo
collabor
bio
ventur
global
health
bvgh
collabor
consortium
partner
broker
access
intellectu
properti
ip
make
access
academ
research
therefor
catalyz
develop
new
even
though
translat
process
scienc
similar
regardless
intend
intervent
drug
vaccin
devic
diagnost
decisionmak
process
chang
depend
busi
case
product
intervent
busi
case
driven
complex
scientif
technic
logist
oper
element
ultim
determin
feasibl
cross
wellknown
valley
death
introduct
postlicensur
phase
effect
profit
financi
realiz
also
call
product
valu
proposit
develop
global
health
technolog
need
prevent
treat
diagnos
chronic
debilit
infecti
diseas
also
known
neglect
tropic
diseas
ntd
mostli
affect
peopl
live
extrem
poverti
busi
case
valu
proposit
driven
much
differ
sometim
uniqu
factor
compar
technolog
intervent
clear
profit
potenti
market
success
effort
increas
effici
reduc
risk
failur
acceler
translat
scienc
highlight
innov
model
build
busi
case
valu
proposit
product
target
ntd
two
decad
ago
product
develop
partnership
pdp
pdp
compris
public
privat
academ
philanthrop
entiti
util
nonprofit
organiz
structur
enabl
collect
secur
fund
advanc
develop
drug
vaccin
health
tool
public
good
product
bring
global
health
innov
solut
current
pharmaceut
compani
unabl
invest
due
inabl
promis
sharehold
return
texa
children
hospit
center
vaccin
develop
texa
children
cvd
baylor
colleg
medicin
nation
school
tropic
medicin
consortium
partner
lead
develop
test
lowcost
effect
vaccin
emerg
ntd
human
hookworm
schistosomiasi
chaga
diseas
ntd
pdp
seek
appli
lesson
learn
commun
vaccinologist
strive
advanc
translat
preclin
research
defin
predict
system
rather
empir
decis
vaccin
candid
enter
clinic
path
intellig
effici
studi
design
furthermor
goal
break
paradigm
vaccin
ntd
measur
busi
case
insuffici
valu
proposit
review
provid
assess
framework
translat
process
use
establish
full
public
health
valu
proposit
busi
case
technolog
address
global
health
gap
ntd
provid
exampl
purpos
focu
two
vaccin
human
hookworm
schistosomiasi
vaccin
provid
perspect
probabl
road
map
forwardlook
opinion
academ
institut
medic
research
organ
pdp
consortium
continu
sourc
biomed
innov
discoveri
progress
mostli
spectat
activ
engag
acceler
advanc
essenti
vaccin
candid
urgent
need
low
middleincom
countri
term
neglect
tropic
diseas
ntd
use
refer
approxim
infect
common
set
major
ntd
parasit
infect
hookworm
infect
schistosomiasi
onchocerciasi
chaga
diseas
leishmaniasi
diseas
tend
chronic
debilit
condit
leprosi
bacteri
fungal
diseas
also
includ
howev
also
viral
ntd
includ
rabi
major
arboviru
infect
dengu
yellow
fever
univers
featur
ntd
disproportion
impact
popul
live
extrem
poverti
box
addit
ntd
also
caus
poverti
advers
health
econom
effect
mani
exhibit
longterm
effect
develop
children
product
work
capac
success
girl
still
anoth
aspect
ntd
gener
major
caus
mortal
fact
ntd
typic
kill
mean
need
evalu
altern
method
express
global
public
health
sever
approach
use
current
measur
impact
first
major
ntd
wide
preval
includ
parasit
helminth
infect
hookworm
schistosomiasi
affect
hundr
million
peopl
howev
viral
ntd
except
diseas
incid
figur
relev
overal
combin
ntd
may
compris
common
afflict
poor
second
metric
commonli
use
report
ntd
disabilityadjust
life
year
dali
refer
year
combin
year
live
disabl
yld
togeth
year
life
lost
yll
disabl
featur
yld
compon
ntd
dali
calcul
predomin
shown
tabl
nine
ntd
current
target
human
vaccin
differ
stage
develop
also
develop
two
vaccin
cysticercosi
echinococcosi
respect
would
use
veterinari
vaccin
prevent
transmiss
term
ntd
target
human
vaccin
accord
global
burden
diseas
gbd
studi
togeth
diseas
affect
approxim
million
peopl
given
popul
larg
repres
world
approxim
million
peopl
believ
live
world
bank
poverti
figur
per
nine
ntd
current
target
human
vaccin
exert
huge
global
health
impact
accord
gbd
togeth
result
million
dali
annual
valu
exce
dali
global
cervic
howev
mani
investig
commun
ntd
scientist
research
feel
even
million
dali
lowbal
estim
exampl
current
diseas
burden
estim
hookworm
infect
may
adequ
encompass
case
sever
moder
anemia
result
current
dali
estim
schistosomiasi
fail
consid
chronic
morbid
endorgan
patholog
well
increas
suscept
hivaid
among
adolesc
girl
thu
full
consider
aspect
ntd
morbid
could
result
least
tripl
gbd
diseas
burden
estim
still
anoth
consider
nine
ntd
would
potenti
target
human
vaccin
econom
multipl
health
econom
estim
ntd
global
among
local
region
studi
primarili
look
econom
burden
ntd
benefit
mass
drug
administr
program
link
addit
studi
focus
healthcar
cost
impact
human
capac
especi
agricultur
worker
women
other
look
costeffect
context
pdp
addit
effort
model
costeffect
ntd
vaccin
link
exampl
model
studi
evalu
hookworm
vaccin
deliv
prevent
chemotherapi
potenti
posit
societ
benefit
time
therefor
costeconom
studi
need
investig
mechan
ntd
antipoverti
vaccin
could
prevent
debilit
diseas
improv
longterm
econom
partnership
academ
public
privat
sector
organ
leverag
expertis
exchang
inform
guid
formal
research
collabor
agreement
program
project
charter
lead
robust
project
pipelin
half
dozen
fund
vaccin
program
differ
stage
develop
figur
advanc
research
develop
r
product
clinic
develop
focu
capac
build
infrastructur
develop
knowledgeshar
meet
low
middleincom
countri
limc
need
world
health
organ
requir
joint
partnership
public
continu
exchang
inform
scientif
confer
partner
meet
workshop
pdp
embed
within
academ
health
center
texa
medic
center
key
research
train
arm
nation
school
tropic
medicin
baylor
colleg
establish
hybrid
model
biotech
academ
cultur
train
next
gener
vaccin
research
traine
learn
site
via
short
exchang
in
technic
oper
system
use
vaccin
develop
contribut
percent
train
investig
work
posit
tackl
ntd
strateg
necess
ensur
continu
sustain
vaccin
program
texa
children
cvd
partner
establish
diversifi
financi
portfolio
obtain
differ
distinct
nation
intern
sourc
fund
cover
specif
area
vaccin
develop
continuum
address
challeng
complex
appli
fund
opportun
base
stage
matur
given
project
addit
fund
project
made
avail
manag
expenditur
fund
encompass
element
account
transpar
essenti
activ
manag
team
dedic
program
project
manag
keep
track
timelin
mileston
decis
point
go
go
criteria
health
econom
model
return
invest
sever
ntd
vaccin
includ
vaccin
hookworm
infect
chaga
diseas
leishmaniasi
clearli
point
major
econom
return
term
improv
product
robust
workforc
reduc
hospit
social
good
translat
overal
nation
addit
model
studi
shown
ntd
vaccin
acceler
control
elimin
povertypromot
especi
hookworm
infect
schistosomiasi
howev
model
evid
support
econom
domin
ntd
antipoverti
vaccin
aspect
yet
suffici
promot
substanti
time
global
invest
end
longtim
horizon
risk
failur
absenc
robust
commerci
market
make
vaccin
daunt
financi
invest
prospect
fuel
investor
hesit
recent
shortcom
public
reaction
newli
introduc
vaccin
malaria
dengu
despit
billiondollar
invest
glaxo
smith
kline
gsk
sanofi
pasteur
top
acceler
global
antivaccin
movement
still
anoth
factor
fact
recent
financi
pull
mechan
advanc
market
commit
prioriti
review
voucher
far
benefit
larger
forprofit
organ
abil
use
intern
resourc
order
advanc
develop
product
realiti
left
remain
vaccin
pdp
often
outsidelookingin
term
invest
ecosystem
despit
hurdl
effort
underway
sustain
ntd
vaccin
framework
part
global
govern
neglect
diseas
vaccin
initi
vaccin
research
ivr
world
health
organ
establish
decad
vaccin
collabor
dovc
coordin
develop
global
vaccin
action
plan
gvap
gvap
provid
framework
embrac
r
translat
scienc
compon
mostli
facilit
product
develop
vaccin
advisori
committe
pdvac
also
take
consider
vaccin
initi
ntd
sever
publish
highlight
articl
review
landscap
vaccin
candid
advanc
develop
base
assess
report
gvap
howev
progress
continu
slow
like
goal
may
challeng
instanc
indic
data
suggest
vaccin
coverag
level
increas
diseas
outbreak
measl
other
continu
occur
challeng
due
multipl
global
region
nation
issu
requir
increas
global
effort
promot
r
increas
immun
campaign
reduc
vaccin
hesit
address
system
weak
limit
equit
vaccin
furthermor
enhanc
knowledgeshar
collabor
r
translat
scienc
agenda
gvap
partnership
us
nation
institut
healthnat
institut
allergi
infecti
diseas
nihniaid
bill
melinda
gate
foundat
bmgf
launch
global
vaccin
immun
research
forum
gvirf
held
everi
two
latest
forum
held
includ
special
focu
gvap
goal
develop
introduc
new
improv
vaccin
technolog
emphasi
thoughtprocess
develop
robust
busi
case
full
public
health
valu
proposit
fphvp
need
make
decis
end
end
develop
integr
deliveri
initi
support
strateg
advisori
group
expert
sage
provid
framework
start
earli
stage
vaccin
product
develop
ensur
clear
definit
global
valu
vaccin
allow
accur
priorit
eventu
avoid
delay
uptak
especi
lmic
gavi
vaccin
allianc
also
made
signific
progress
support
make
vaccin
equit
afford
exampl
organ
work
togeth
point
develop
licensur
introduct
menafrivac
vaccin
meningococc
diseas
africa
mening
belt
reduc
incid
suspect
mening
epidem
risk
effect
confirm
group
meningococc
understand
fphvp
ntd
vaccin
necessari
step
build
busi
case
primarili
provid
inform
need
geograh
popul
burden
also
assist
set
appropri
target
product
profil
product
develop
regulatori
strategi
ultim
propos
advocaci
polici
public
health
activ
need
ensur
demand
adopt
implement
recent
year
scientif
vaccin
commun
thoughtlead
advoc
fphvp
includ
assess
relat
individu
benefitrisk
individu
random
clinic
trial
translat
scienc
public
health
intervent
comprehens
includ
evalu
popul
impact
commun
benefitsrisk
elegantli
describ
gessner
et
al
fphvp
vaccin
includ
wider
scope
vaccin
benefit
limit
assess
base
sole
econom
vaccinationset
health
benefit
rather
includ
nonhealth
benefit
includ
product
healthrisk
reduct
equityfair
fiscal
ntd
emerg
emerg
infecti
diseas
process
decis
hamper
percept
develop
cost
substanti
implicit
market
failur
lead
limit
financi
return
invest
exampl
epidem
infecti
diseas
recent
studi
gougla
et
highlight
pandem
diseas
requir
vaccin
stockpil
model
includ
parallel
develop
multipl
candid
multipl
diseas
focu
platform
known
success
regulatori
pathway
howev
even
approach
cost
bring
discoveri
phase
could
million
addit
consider
given
logist
abil
efficaci
trial
cost
estim
bring
discoveri
trough
licensur
could
amount
billion
furthermor
probabl
success
vaccin
candid
advanc
preclin
clinic
usual
rang
success
phase
probabl
goe
roadmap
assess
translat
success
human
hookworm
schistosomiasi
vaccin
requir
indepth
analysi
technic
oper
profit
driver
gener
vaccin
develop
program
relat
ntd
roadmap
perceiv
fragment
slow
expens
poorli
coordin
import
stakehold
govern
nonprofit
academ
entiti
sometim
even
lack
engag
public
recent
public
highlight
technic
step
prospect
lesson
learn
use
texa
children
cvd
effort
follow
critic
path
develop
human
hookworm
schistosomiasi
among
greatest
challeng
develop
vaccin
biolog
neglect
emerg
infecti
diseas
mechan
secur
fund
develop
stage
rank
high
multipl
attempt
made
gener
blueprint
mostli
led
would
ideal
model
bring
new
biolog
preclin
clinic
develop
last
mile
toward
licensur
registr
howev
even
mani
consult
substanti
financi
support
mechan
provid
organ
bmgf
wellcom
trust
multilater
govern
andor
pharmaceut
compani
ideal
model
proven
success
fill
shortcom
certainli
design
fitfor
neglect
emerg
infecti
diseas
abl
bring
target
vaccin
eventu
object
success
licensur
fund
develop
new
ntd
vaccin
come
govern
philanthrop
fund
occasion
biotech
fund
seldom
fund
rais
privat
equiti
govern
fund
unit
state
fund
strategi
use
nation
institut
health
nih
biotechnolog
research
support
primarili
earli
stage
preclin
r
rather
transit
new
vaccin
advanc
develop
commerci
emphasi
laboratori
discoveri
remain
stuck
within
valley
death
even
discoveri
arriv
clinic
applic
set
path
toward
advanc
develop
substanti
nih
fund
small
busi
innov
research
sbir
pathway
fund
gener
avail
nonprofit
pdp
recent
nih
nation
institut
allergi
infecti
diseas
niaid
made
select
gap
fund
avail
pdp
contract
mechan
fund
possibl
particip
niaidnih
network
vaccin
trial
evalu
unit
vteu
good
laboratori
practic
glp
toxicolog
contractor
critic
path
element
advanc
schistosomiasi
vaccin
niaidnih
also
directli
support
earli
clinic
trial
hookworm
schistosomiasi
vaccin
outsid
nih
depart
defens
dod
provid
need
support
earlystag
vaccin
develop
congression
direct
medic
research
program
cdmrp
instrument
advanc
leishmaniasi
vaccin
unit
kingdom
europ
promis
research
vaccin
support
organ
innov
medicin
initi
european
commiss
fund
come
horizon
mechan
similarli
us
mechan
typic
bring
innov
discoveri
commerci
path
new
coalit
epidem
prepared
innov
cepi
allianc
chosen
focu
mostli
perceiv
viral
pandem
threat
lassa
fever
mer
coronaviru
infect
nipah
viru
infect
rather
povertypromot
debilit
ntd
privat
invest
ntd
vaccin
major
philanthropi
also
tepid
gate
foundat
gradual
divest
space
order
focu
either
altern
technolog
elimin
strategi
although
wellcom
trust
begun
priorit
aspect
vaccin
develop
ebola
emerg
infect
recent
carlo
slim
foundat
commit
support
vaccin
combat
chaga
diseas
overal
assess
global
health
technolog
commun
larg
pivot
away
ntd
vaccin
order
either
focu
diseas
emerg
prepared
especi
threaten
north
america
europ
ntd
invest
focus
innov
lower
risk
shorter
timelin
highlight
recent
commentari
vaccin
candid
poor
nation
go
wast
develop
ntd
vaccin
requir
help
advanc
toward
licensur
success
enter
vaccin
candid
ntd
pipelin
even
option
public
privat
market
therefor
vaccin
need
reli
primarili
public
market
lmic
highrisk
develop
prospect
ad
difficulti
predict
accur
return
invest
recent
observ
surpris
burden
ntd
occur
among
poor
live
wealthi
group
nation
group
sometim
refer
poorest
rich
potenti
point
way
bring
govern
invest
outsid
us
unit
kingdom
howev
framework
known
blue
marbl
health
yet
wide
accept
leader
policymak
describ
commentari
knowledg
gap
mechan
protect
lack
clear
understand
burden
diseas
especi
area
differ
endem
intens
clear
pictur
costofil
region
given
countri
make
difficult
argument
establish
valu
proposit
therefor
join
rest
scientif
commun
ask
call
action
case
strongli
encourag
new
path
develop
vaccin
compel
uncertain
busi
case
urg
commun
reevalu
includ
futur
path
vaccin
low
artifici
financi
opportun
potenti
return
quantifi
primarili
via
public
health
mean
recent
invest
vaccin
combat
viral
diseas
pandem
potenti
emerg
diseas
exclud
invest
antipoverti
vaccin
combat
ntdsdespit
demonstr
cost
save
econom
domin
major
global
health
investor
pivot
away
ntd
vaccin
order
focu
lowerrisk
technolog
shorter
timelin
horizonsantipoverti
vaccin
ntd
urgent
need
new
busi
model
develop
due
rise
r
cost
need
stringent
clinic
trial
exhaust
manufactur
rule
regulatori
frameworksvaccin
demand
rise
complex
diseas
requir
better
faster
develop
time
implement
new
deliveri
model
hamper
vaccin
hesit
poor
advocacyth
probabl
new
vaccin
reach
market
half
approxim
probabl
drugsgiven
complex
develop
high
risk
involv
innov
way
measur
return
need
attract
investor
better
transpar
need
predict
r
spend
clinic
develop
market
entri
gener
span
millionorganiz
methodolog
cultur
barrier
within
among
research
institut
necessaryw
urgent
need
innov
financ
sector
identifi
new
sustain
busi
model
urgent
need
technologiesw
propos
new
call
action
ntd
vaccin
